

**DIVISION OF OTC DRUG PRODUCTS
CENTER FOR DRUG EVALUATION AND RESEARCH**

ANNOUNCEMENT OF OTC DRUG FEEDBACK MEETING

BETWEEN: **Representatives of FDA**

and

Bayer HealthCare, LLC

TOPIC: **A discussion of Citizens Petition 16 (Docket No. 77N-0094). This petition requests amendment of the Final Rule for Professional Labeling for Aspirin to include the use of 75 mg-325mg aspirin for the primary prevention of myocardial infarction. Information from the December 8, 2003 Advisory Committee meeting regarding this topic will also be discussed.**

DATE: **April 30, 2004**

TIME: **3:00 p.m. – 4:30 p.m.**

LOCATION: **Conference Room G
Woodmont II
1451 Rockville Pike
Rockville, MD 20852**

Pursuant to the agency's policy statement published in the FEDERAL REGISTER of September 29, 1981 (46 FR 47740) and clarified April 1, 1983 (48 FR 14050) and February 4, 1985 (50 FR 4916), which includes provisions for agency meetings with industry or other interested persons, this feedback meeting is being announced.

All feedback meetings are open to the public and no prior reservation is necessary. For further information or to reconfirm that the meeting has not been rescheduled or canceled, call Walter Ellenberg, Ph.D., 301-827-2222.

ATTENTION: JENNIE BUTLER

cc: Docket No. 77N-0094

DATE FORWARDED: __April 15, 2004__